FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> Prevnar | Japan | Sanofi-Aventis | Pfizer

Pfizer's Prevnar and Sanofi's ActHIB cleared for Japanese market

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!



Tools

After nearly three weeks of suspended vaccinations, Japan has cleared the path for Sanofi-Aventis' ActHIB and Pfizer's Prevnar--marketed as Prevenar--to return to the Japanese market as soon as April 1. The vaccines, ActHIB for hemophilius influenza and meningitis and pneumonia preventative Prevnar, were originally called off the market after five children between the ages of six months and two years died after receiving one or both of the vaccines. Soon after, the Japanese health ministry cleared the vaccines of any connection to the deaths, but the embargo remained in place.

Both companies released statements noting that the Ministry of Health, Labour, and Welfare's Safety Measures Investigation Committee and Post-Vaccination Adverse Event Study panel reaffirmed the vaccines' innocence in the children's deaths.

- see the WSJ piece
- read Bloomberg's coverage

Related Articles:
Japan finds no vaccine link to child deaths
Japan suspends Pfizer, Sanofi shots after deaths


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:

More stories about Pfizer   Prevnar   Japan   Sanofi-Aventis